Bachem celebrates 40th anniversary

June 29, 2011

Bubendorf/Basel, June 29, 2011 – Bachem AG (SIX: BANB), market leader in
peptide-based active pharmaceutical ingredients for the pharma and biotech
industry, celebrates its 40th anniversary today. The past 40 years have seen
the group develop from a small start-up to the clear market leader. Bachem
enjoys an excellent reputation as a reliable partner to its customers all over the
world.

Bachem took its first step into the American market by establishing a subsidiary there
in 1987. In 1996 it acquired its largest competitor Bachem Inc., Torrance, California.
The acquisition of Peninsula Laboratories, San Carlos, California in 1999 marked
another milestone. Bachem’s 2001 takeover of Sochinaz SA in Vionnaz, Switzerland
significantly expanded production capacity. Bachem Group now has a global
workforce of about 700 people, including 530 in Switzerland.

Full service
Bachem manufactures more than 9,000 products for the research market, of which
more than 4,000 are bioactive peptides for the biotech and pharma industry, at its
sites in the USA, UK, Germany and Switzerland. Product distribution is mainly via
company-owned sales and marketing organizations in Europe and America.
Customers benefit from Bachem’s extensive expertise and experience, which form
the basis for a full range of services tailored to meet specific customer requirements.
Dr. Peter Grogg, company founder and Chairman of the Board of Directors,
commented: “Thanks to our professional and exceptionally dedicated staff, we have
earned world leadership in our core business over the past number of years. It’s an
achievement we are proud of. Our commitment to quality with our label Quality
Matters pledges us to continue delivering top quality products and services to our
customers now and in the future.”
To mark the anniversary, Bachem is hosting a celebration with European staff and
invited guests on September 16 in Bubendorf, and a brunch for the local population
of Bubendorf on September 17. The celebration with US staff takes place in Los
Angeles on September 30.

 

About Bachem
Bachem is an independent, public biochemicals company providing full service to the
pharma and biotech industry. Bachem is specialized in the process development and
the manufacturing of peptides and complex organic molecules as active
pharmaceutical ingredients (APIs), as well as innovative biochemicals for research
purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and
the US, Bachem works on a global scale and holds a leading position in the field of
peptides.
Bachem has been listed on the Swiss stock exchange since 1998 and publishes an
extensive annual report. The annual report and more information about Bachem are
available for viewing on the redesigned website at www.bachem.com.